Acadia cut its full-year 2025 adjusted EBITDA outlook to USD 601 million-611 million from USD 650 million-660 million. The company said the revision followed an annual third-party actuarial review of PLGL costs, with 2025 PLGL expenses projected at about USD 116 million versus USD 54 million in 2024. Acadia cited higher patient-related litigation, including increased claim frequency and higher expected settlement costs, as factors behind the higher PLGL projection.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acadia Healthcare Company Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603160900PRIMZONEFULLFEED9665931) on March 16, 2026, and is solely responsible for the information contained therein.
Comments